Latest Ratios: P/E Ratio -3.7x · EV/EBITDA N/A · ROE -1569.1%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $14M | $8M | — | — | — | — |
| Enterprise Value | $12M | $6M | — | — | — | — |
| P/E Ratio → | -3.75 | — | — | — | — | — |
| P/S Ratio | 370.38 | 164.12 | — | — | — | — |
| P/B Ratio | 3.49 | 1.62 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 111.31 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | -1.3% | -1.3% | -6.3% | 36.3% | 35.3% | 39.4% |
| Operating Margin | -9154.6% | -9154.6% | -3404.9% | -1060.1% | -2077.4% | -944.8% |
| Net Profit Margin | -9366.8% | -9366.8% | -3229.5% | -1111.0% | -1933.8% | -888.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -1569.1% | -1569.1% | — | — | — | — |
| ROA | -91.2% | -91.2% | -93.7% | -74.1% | -91.6% | -54.5% |
| ROIC | — | — | — | — | — | — |
| ROCE | -835.6% | -835.6% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.52 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -312.10 | -312.10 | -39.54 | -18.19 | -538.00 | -185.74 |
Net cash position: cash ($3M) exceeds total debt ($482719)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | 2.35 | 0.27 | 0.32 | 0.41 | 0.54 |
| Quick Ratio | 2.35 | 2.35 | 0.27 | 0.32 | 0.41 | 0.54 |
| Cash Ratio | 1.00 | 1.00 | 0.02 | 0.01 | 0.18 | 0.51 |
| Asset Turnover | — | 0.01 | 0.03 | 0.06 | 0.04 | 0.06 |
| Inventory Turnover | — | — | 29.68 | 8.37 | 5.63 | — |
| Days Sales Outstanding | — | 1872.40 | 902.47 | 767.45 | 2837.78 | 121.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $3M | $3M | $3M | $3M | $3M |
Commercial scale and liquidity
Based on reported figures, the P/S ratio of 370.38 suggests that the market is pricing the company as a high-growth speculative option rather than a traditional healthcare firm, as current revenue levels remain insufficient to justify such a significant premium over the underlying asset base.
The valuation appears entirely decoupled from fundamental performance, as the lack of positive earnings renders traditional P/E metrics meaningless. Investors should monitor whether this premium is driven by the potential for regional expansion or if it reflects a misunderstanding of the company's current commercial limitations.
As indicated by the reported gross margin of -1.29%, the company is currently unable to cover the direct costs of its specialized laboratory operations, highlighting a structural inability to achieve the necessary production volume required to offset the high fixed costs of maintaining sterile, climate-controlled biological environments.
The operating margin of -9154% confirms that administrative and research expenditures are entirely decoupled from current revenue generation. This suggests that the firm is currently in a pre-commercial phase where profitability is not a near-term objective, but rather a hurdle that requires a massive increase in scale to overcome.
According to the company's financial disclosures, the $3.1 million cash position provides a necessary buffer for current operations, though the lack of meaningful revenue generation suggests this liquidity is being consumed rapidly to sustain the firm's specialized, high-fixed-cost laboratory infrastructure and ongoing regulatory compliance efforts.
While the current ratio appears adequate for short-term obligations, the lack of recurring revenue streams makes the company highly vulnerable to capital market volatility. Investors should monitor the burn rate closely, as the absence of debt financing implies that any future liquidity needs will likely require dilutive equity issuance.
The P/S ratio is the most commonly misapplied metric for this business model, as it obscures the reality that the company's revenue is currently a function of early-stage clinical adoption rather than a scalable, repeatable commercial process that can be extrapolated to determine long-term enterprise value.
Instead of relying on revenue multiples, analysts should focus on the 'cost-per-treatment' and 'hospital formulary inclusion rate' as more accurate indicators of future viability. Using P/S in this context may lead to an overestimation of the company's market penetration and a failure to account for the high logistical costs inherent in the MDT sector.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CUPR stock.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's current P/E ratio is -3.7x. This places it at the 50th percentile of its historical range.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's return on equity (ROE) is -1569.1%.
Based on historical data, Cuprina Holdings (Cayman) Limited Class A Ordinary Shares is trading at a P/E of -3.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares has -1.3% gross margin and -9154.6% operating margin.